Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Haplo-Identical Bone Marrow Transplantation, "The Glass is Always Half Full"
  • USA - English


News provided by

[email protected]

Sep 21, 2014, 03:00 ET

Share this article

Share toX

Share this article

Share toX

New Delhi (PRWEB) September 21, 2014 -- A 25 year old IT professional was struck with Hodgkin ’s disease which is one of the most curable cancers. He was treated with standard chemotherapy and the disease went away only to reappear a few months later. This time he received local radiation and Autologous Bone Marrow Transplantation (BMT). However, the response was short lived and the cancer sprung its ugly head within 6 months.

The young man and his distraught family went from one centre to another. Various forms of chemotherapy and a new drug called Brentuximab were suggested to him by the experts. However, the drug Brentuximab had to be imported and each cycle of treatment would have costed 5 lakhs. Some had suggested an Allogeneic BMT but his only brother was fully mismatched with him and this option was no longer a consideration.

Dr Suparno Chakrabarti and Dr Sarita Jaiswal had been running a HAPLOIDENTICAL BMT PROGRAM in the country for 3 years and the patient and his father came to them at Dharamshila BMT Centre (http://bmthospitalindia.com) despite all the other experts in the country discouraging them to go for such an option. At the outset, the patient was given standard chemotherapy which showed an initial response, but as it had happened so many times before, the cancer bounced back. The patients parents were half matched with him as expected, but the team at Dharamshila realised that just doing the BMT is not going to help the young man. They identified a unique population of white blood cells in the father, but not in the mother which could kill the tumour cells without causing any adverse reaction in the patient. They are called ‘KIR ligand mismatched NK cells’’. These cells were analysed and were found very effective in killing tumour cells in the test tube. Dr Sarita Jaiswal had been trained in transplants involving such cell manipulations at Italy and USA. The patient’s body could not have received any further intensive chemotherapy. They sought help from Dr Kanika Sharma to administer a small dose of radiation to the entire body keeping in mind that he has already received a very large dose of radiation to his heart, lungs and neck. With this tiny dose of radiation and some immuno suppressive drugs the patient was infused half matched cells from his father and 7 days later his father’s white cells were collected and the special cells were separated and infused to the patient.

The stem cells from the father started growing in the patient after 2 weeks and he remained free of all bacterial and viral infections since then. The blood and bone marrow of the patient were regularly analysed and it showed that the cells from the father which were supposed to be killing the tumour without causing any reaction in the patient, were growing in number. Sixty days after the BMT, a PET scan was done to see the state of the cancer. To everyone’s joy and surprise, it had disappeared completely.

Few such cases have been reported worldwide and this is the first time Indian doctors have used innovation, science and technology to cure such a refractory cancer. Dr Sarita Jaiswal had seen some very impressive results with Haploidentical BMT using cell manipulation, but to replicate the procedure in its entirety would cost 40 lakhs at least. Hence, Dr Sarita innovated this unique way of carrying out the Half matched BMT at a low cost and administer selective cells at the right time which shall help in hitting the tumour as well as fighting infections.

Several such Haploidentical BMT using this unique and innovative technology are being carried out by Dr Sarita Jaiswal at Dharamshila BMT Centre. Dr Sarita says that it is not just about giving the cells but understanding the science behind it and applying it in the right context in the correct way. Dr Suversha Khanna, who had long dreamt of a BMT unit at Dharamshila Hospital expressed her satisfaction at the optimum utilisation of the world class infrastructure so painstakingly erected in the hospital, 20 years after its inception. She said that that there is little point in having yet another BMT centre, if it’s not going to make a difference to the majority of the suffering patients. Today, with the infrastructure and the expertise of the BMT team, ably supported by Radiation Oncologists, its possible that every patient who needs a BMT can have one from a Half matched (HAPLOIDENTICAL) Parents, Siblings or Children and with the right choice of donor can even get cured of otherwise refractory blood or lymph gland cancers. Dr Suparno Chakrabarti who had started such transplants for the first time in India says that the ‘glass is always half full’.

ABOUT DHARAMSHILA HOSPITAL AND RESEARCH CENTRE

Passion for Excellence in Cancer Care

A group of concerned relatives and friends of cancer patients felt the need to provide complete cancer treatment under one roof. They felt it was their “Dharma” (duty) to provide to cancer patients what was not available to their near and dear ones, when they were suffering from cancer. They laid the “Shila” (foundation) of their duty by registering a NGO, Dharamshila Cancer Foundation And Research Centre (DCFRC) on 19 April, 1990.

DCFRC Commissioned the first phase of the Dharamshila Cancer Hospital And Research Centre (DCHRC) with 100 beds in 1994 and expanded to 300 beds in 2006, with the sole objective of making cancer treatment available, accessible and affordable.

Being totally focused on cancer for more than two decades, Dharamshila is continuously adding world class cutting edge technologies for early diagnosis and cancer treatment.

Dharamshila Hospital is the most trusted cancer hospital for patients from all over India and neighbouring countries for its policy of avoiding unnecessary procedures/hospitalization and transparent billing. Dharamshila hospital has won the goodwill of thousands of Patients who are enjoying cancer free life.

Highly qualified skilled and experienced teams of organ specific cancer specialists practice evidence based medicine and follow international treatment guidelines to achieve best treatment outcomes.

Being sensitive to the physical, medical, emotional and financial needs of patients, Dharamshila strives to serve patients with love, devotion, compassion, commitment and positive attitude.
High quality standards of treatment, complete patient safety and satisfaction, improving cure rates and adding quality to life will always remain our hallmark.

PIONEERING STEPS

• First comprehensive cancer care centre of North India, commissioned in 1994.

• First cancer hospital of India to start CliniMACS based TCR alfabeta depleted Haplo-identical Bone Marrow Transplantation in BMT unit designed as per (half matched) International standards 1000 for clean rooms.

• Only cancer hospital of North India doing most challenging Head and Neck Surgeries with results at par with European Cancer Institutes.

• First and Only Cancer Hospital of Delhi, offering Third Generation Radiation Technology i.e. Elekta Synergy VMAT with IMRT, IGRT, SBRT and SRS / SRT and Respiratory Gating Capabilities and best Treatment Planning systems like Monaco, CMSxi0, ERGO++ and Plato.

• First cancer hospital of India accredited by National Accreditation Board for Hospitals and Healthcare Providers (NABH) in 2008.

• First cancer hospital of North India accredited by National Accreditation Board for Testing and Calibration Laboratories (NABL) in 2010.

• First cancer hospital in India, certified for implementing integrated Quality and Environment Management systems conforming to ISO 9001:2008 and ISO 14001:2004 standards by TUV-NORD, Germany in 2002.

• First hospital of India, given accreditation by National Board of Examination (NBE) for the Diplomate National Board (DNB) Programme in medical and surgical oncology in 2001 and 2004 respectively.

• First Cancer Hospital of North India to Start Post Basic Diploma in Oncology Nursing (PBDON) in 2010.

Dr. Suversha Khanna, [email protected], +91 8130000120, [email protected]

Modal title

Dharamshila Blood and Marrow Stem Cell Transplant Centre
Dharamshila Blood and Marrow Stem Cell Transplant Centre
Dharamshila Blood and Marrow Stem Cell Transplant Centre

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.